

# Geoffrey Weiss

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1545761/publications.pdf>

Version: 2024-02-01

133  
papers

13,669  
citations

29994

54  
h-index

20307

116  
g-index

134  
all docs

134  
docs citations

134  
times ranked

9306  
citing authors

#	ARTICLE	IF	CITATIONS
1	Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation. <i>Oncologist</i> , 2021, 26, 224-230.	1.9	2
2	MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. , 2020, 8, e000262.		44
3	A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2018, 94, 329-339.	0.9	36
4	Understanding Advanced Prostate Cancer Decision Making Utilizing an Interactive Decision Aid. <i>Cancer Nursing</i> , 2018, 41, 2-10.	0.7	19
5	Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2028-2036.	0.8	111
6	Melanoma NOS1 expression promotes dysfunctional IFN signaling. <i>Journal of Clinical Investigation</i> , 2014, 124, 2147-2159.	3.9	40
7	A theory-based decision aid for patients with cancer: results of feasibility and acceptability testing of DecisionKEYS for cancer. <i>Supportive Care in Cancer</i> , 2013, 21, 889-899.	1.0	20
8	Clinical Activity and Safety of Combination Therapy with Temezirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47). <i>Clinical Cancer Research</i> , 2013, 19, 3611-3620.	3.2	46
9	Surgical Management of the Patient with Metastatic Melanoma to the Heart. <i>Journal of Cardiac Surgery</i> , 2013, 28, 124-128.	0.3	7
10	Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 619-627.	0.7	189
11	Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 7440-7450.	3.2	74
12	Helical Tomotherapy-Based STAT RT: Dosimetric Evaluation for Clinical Implementation of a Rapid Radiation Palliation Program. <i>Medical Dosimetry</i> , 2010, 35, 280-286.	0.4	8
13	Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. <i>Cancer</i> , 2009, 115, 5117-5125.	2.0	59
14	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma. <i>Cancer</i> , 2008, 113, 2139-2145.	2.0	77
15	Unresectable Cholangiocarcinoma: Comparison of Survival in Biliary Stenting Alone Versus Stenting With Photodynamic Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 290-297.	2.4	184
16	Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds $\alpha 5 \beta 1$ Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study. <i>Clinical Cancer Research</i> , 2008, 14, 7924-7929.	3.2	169
17	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 165-174.	1.1	45
18	Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil: Southwest Oncology Group Study 9024. <i>Journal of Urology</i> , 2006, 176, 548-553.	0.2	12

#	ARTICLE	IF	CITATIONS
19	Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 298-305.	1.2	22
20	Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 5207-5215.	3.2	61
21	Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non-Small-Cell Lung Cancer: SWOG S9712. <i>Journal of Clinical Oncology</i> , 2006, 24, 5242-5246.	0.8	34
22	Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914. <i>Journal of Thoracic Oncology</i> , 2006, 1, 991-995.	0.5	5
23	Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 133-141.	0.8	746
24	Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1819-1825.	0.8	109
25	THE MODULATION OF PROSTATE CANCER RISK WITH $\alpha$ -TOCOPHEROL: A PILOT RANDOMIZED, CONTROLLED CLINICAL TRIAL. <i>Journal of Urology</i> , 2005, 174, 519-522.	0.2	21
26	A phase II clinical trial of oral bropiramine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: A Southwest Oncology Group Study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 386-389.	0.8	10
27	NF- $\kappa$ B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. <i>Annals of Oncology</i> , 2004, 15, 885-890.	0.6	116
28	Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG) Tj ETQq0 0 0 rgBT /Overlock 10	3.2	49
29	Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small-Cell Lung Cancer: Southwest Oncology Group 9713. <i>Journal of Clinical Oncology</i> , 2004, 22, 127-132.	0.8	47
30	A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms. <i>Clinical Cancer Research</i> , 2004, 10, 1645-1656.	3.2	30
31	Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. <i>Gynecologic Oncology</i> , 2004, 95, 506-512.	0.6	25
32	Doegje-Potter Syndrome: Hypoglycemia Associated with Malignant Solitary Fibrous Tumor. <i>Medical Oncology</i> , 2003, 20, 403-408.	1.2	52
33	Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial. <i>Gynecologic Oncology</i> , 2003, 88, 282-288.	0.6	11
34	Current issues in the management of advanced squamous cell carcinoma of the penis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 431-438.	0.8	13
35	Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3133-3140.	0.8	307
36	Phase I Study of the Intravesical Administration of Recombinant Human Interleukin-12 in Patients With Recurrent Superficial Transitional Cell Carcinoma of the Bladder. <i>Journal of Immunotherapy</i> , 2003, 26, 343-348.	1.2	69

#	ARTICLE	IF	CITATIONS
37	Troxacitabine, an L-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2002, 20, 96-109.	0.8	20
38	Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2002, 20, 2058-2066.	0.8	206
39	Phase II Trial of Recombinant Human Interleukin-4 in Patients With Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study. <i>Journal of Immunotherapy</i> , 2002, 25, 352-358.	1.2	44
40	Management of locally advanced bladder cancer: early vs deferred chemotherapy. <i>World Journal of Urology</i> , 2002, 20, 175-182.	1.2	3
41	Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2002, 128, 214-218.	1.2	134
42	Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel. <i>Journal of Clinical Oncology</i> , 2001, 19, 2493-2503.	0.8	34
43	Outpatient Biochemotherapy With Interleukin-2 and Interferon Alfa-2b in Patients With Metastatic Malignant Melanoma: Results of Two Phase II Cytokine Working Group Trials. <i>Journal of Clinical Oncology</i> , 2001, 19, 3194-3202.	0.8	58
44	Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 3210-3218.	0.8	1,072
45	Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog With Topoisomerase Inhibitory Properties. <i>Journal of Clinical Oncology</i> , 2001, 19, 2937-2947.	0.8	38
46	Phase II Trial of Oral Altretamine for Consolidation of Clinical Complete Remission in Women with Stage III Epithelial Ovarian Cancer: A Southwest Oncology Group Trial (SWOG-9326). <i>Gynecologic Oncology</i> , 2001, 82, 317-322.	0.6	31
47	A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG) Tj ETQq1 1 0.784314 rgBT /Overlo	1.2	14
48	A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2000, 11, 333-338.	0.6	16
49	Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2000, 18, 167-167.	0.8	25
50	Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 1999, 17, 1095-1095.	0.8	65
51	Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 1999, 17, 2604-2604.	0.8	116
52	Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 1999, 17, 1915-1915.	0.8	71
53	Phase II trial of biochemotherapy with interferon $\beta$ , dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999, 125, 292-296.	1.2	12
54	High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. <i>Journal of Clinical Oncology</i> , 1999, 17, 2105-2105.	0.8	1,810

#	ARTICLE	IF	CITATIONS
55	A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. <i>Investigational New Drugs</i> , 1998, 16, 57-67.	1.2	0
56	Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). <i>Investigational New Drugs</i> , 1998, 16, 171-173.	1.2	18
57	13-cis-Retinoic Acid or All-trans-Retinoic Acid plus Interferon- $\alpha$ in Recurrent Cervical Cancer: A Southwest Oncology Group Phase II Randomized Trial. <i>Gynecologic Oncology</i> , 1998, 71, 386-390.	0.6	35
58	Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. <i>Annals of Oncology</i> , 1998, 9, 733-738.	0.6	69
59	Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2459-2465.	0.8	542
60	Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.. <i>Journal of Clinical Oncology</i> , 1998, 16, 664-669.	0.8	58
61	A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea. <i>Blood</i> , 1998, 91, 1533-1541.	0.6	1
62	Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. <i>Annals of Oncology</i> , 1997, 8, 1003-1008.	0.6	32
63	Pityriasis rubra pilaris as an Initial Presentation of Hepatocellular Carcinoma. <i>Dermatology</i> , 1997, 194, 166-167.	0.9	23
64	Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study.. <i>Journal of Clinical Oncology</i> , 1997, 15, 2414-2419.	0.8	82
65	Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.. <i>Journal of Clinical Oncology</i> , 1996, 14, 1128-1135.	0.8	326
66	A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. <i>Annals of Oncology</i> , 1996, 7, 491-496.	0.6	42
67	A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer. <i>Anti-Cancer Drugs</i> , 1996, 7, 402-409.	0.7	2
68	Vitiligo and Gravesâ€™ Disease following Treatment of Malignant Melanoma with Recombinant Human Interleukin 4. <i>Dermatology</i> , 1996, 192, 283-285.	0.9	12
69	Pharmacokinetic profile of Mitoguazone (MGBC) in patients with AIDS related non-Hodgkin's lymphoma. <i>Investigational New Drugs</i> , 1996, 14, 227-234.	1.2	10
70	Phase II Trial of CHIP for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1995, 18, 400-402.	0.6	6
71	Deoxyspergualin. <i>Anti-Cancer Drugs</i> , 1995, 6, 229-236.	0.7	11
72	A Phase II Study of the Continuous Intravenous Infusion of Interleukin-6 for Metastatic Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 1995, 18, 52-56.	1.2	19

#	ARTICLE	IF	CITATIONS
73	A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study. <i>Cancer</i> , 1995, 75, 815-820.	2.0	152
74	A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A southwest oncology group study. <i>Cancer</i> , 1995, 76, 2248-2252.	2.0	67
75	Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.. <i>Journal of Clinical Oncology</i> , 1995, 13, 2895-2899.	0.8	87
76	Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.. <i>Journal of Clinical Oncology</i> , 1995, 13, 1303-1311.	0.8	334
77	Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.. <i>Journal of Clinical Oncology</i> , 1995, 13, 2924-2930.	0.8	78
78	A Phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 35, 397-402.	1.1	14
79	Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 1994, 12, 1553-1560.	0.8	129
80	A Phase II Clinical Trial of Interleukin-2 and Lymphokine-Activated Killer Cells in Advanced Colorectal Carcinoma. <i>Journal of Immunotherapy</i> , 1994, 15, 74-78.	1.2	31
81	Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma. <i>Journal of Immunotherapy</i> , 1994, 15, 147-153.	1.2	58
82	A Phase II Trial of DaunoXome, Liposome- Encapsulated Daunorubicin, in Patients with Metastatic Adenocarcinoma of the Colon. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994, 17, 498-501.	0.6	31
83	Phase II Trials of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Advanced Breast Carcinoma and Carcinoma of the Lung, Ovary, and Pancreas and Other Tumors. <i>Journal of Immunotherapy</i> , 1994, 16, 216-223.	1.2	28
84	Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812). <i>Anti-Cancer Drugs</i> , 1994, 5, 520-526.	0.7	41
85	A phase I clinical and pharmacokinetic study of the oral and the oral/ intravenous administration of menogaril. <i>Investigational New Drugs</i> , 1993, 11, 17-27.	1.2	5
86	Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer. <i>Investigational New Drugs</i> , 1993, 11, 81-83.	1.2	3
87	A phase II trial of piroxantrone in adenocarcinoma of the pancreas. <i>Investigational New Drugs</i> , 1993, 11, 329-331.	1.2	11
88	Phase I and pharmacokinetic trial of weekly CPT-11.. <i>Journal of Clinical Oncology</i> , 1993, 11, 2194-2204.	0.8	274
89	Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 1993, 11, 661-670.	0.8	198
90	Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.. <i>Journal of Clinical Oncology</i> , 1993, 11, 1496-1505.	0.8	42

#	ARTICLE	IF	CITATIONS
91	Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.. Journal of Clinical Oncology, 1993, 11, 1969-1977.	0.8	175
92	Salmonella arizonae peritonitis secondary to ingestion of rattlesnake capsules for gastric cancer.. Journal of Clinical Oncology, 1993, 11, 2288-2289.	0.8	9
93	An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.. Journal of Clinical Oncology, 1993, 11, 1276-1285.	0.8	438
94	Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.. Journal of Clinical Oncology, 1993, 11, 873-878.	0.8	146
95	Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.. Journal of Clinical Oncology, 1993, 11, 950-958.	0.8	132
96	A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-Cancer Drugs, 1992, 3, 337-346.	0.7	98
97	Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. European Journal of Cancer, 1992, 28, 477-478.	1.3	20
98	A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: A Southwest Oncology Group trial. Gynecologic Oncology, 1992, 45, 303-306.	0.6	21
99	Malignant Melanoma in a Hispanic Male with Nevus of Ota. Dermatology, 1992, 185, 146-150.	0.9	27
100	Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.. Journal of Clinical Oncology, 1992, 10, 881-889.	0.8	234
101	A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.. Journal of Clinical Oncology, 1992, 10, 275-281.	0.8	148
102	Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investigational New Drugs, 1992, 10, 239-253.	1.2	559
103	Phase II trial of didemnin-B in advanced epithelial ovarian cancer. Investigational New Drugs, 1992, 10, 23-24.	1.2	19
104	Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest oncology group study. European Journal of Cancer & Clinical Oncology, 1991, 27, 135-138.	0.9	23
105	A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.. Journal of Clinical Oncology, 1991, 9, 641-648.	0.8	100
106	A phase I trial of taxol given by a 6-hour intravenous infusion.. Journal of Clinical Oncology, 1991, 9, 1261-1267.	0.8	171
107	Phase I evaluation of 773U82 HCl, a member of a new class of DNA intercalators. Anti-Cancer Drugs, 1991, 2, 357-364.	0.7	1
108	Phase II Trial of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Hodgkin's Disease and Non-Hodgkin's Lymphom. Journal of Immunotherapy, 1991, 10, 214-220.	1.2	26

#	ARTICLE	IF	CITATIONS
109	Phase I Clinical and Pharmacokinetic Trial of Flavone Acetic Acid. Journal of the National Cancer Institute, 1991, 83, 124-128.	3.0	22
110	Phase I Evaluation of Crisnatol (BWA770U Mesylate) on a Monthly Extended Infusion Schedule. Selective Cancer Therapeutics, 1991, 7, 85-91.	0.5	1
111	Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus Versus Infusion in Patients With Soft-Tissue Sarcomas: A Southwest Oncology Group Study. Journal of the National Cancer Institute, 1991, 83, 926-932.	3.0	155
112	Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.. Journal of Clinical Oncology, 1990, 8, 1630-1636.	0.8	84
113	Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.. Journal of Clinical Oncology, 1990, 8, 1138-1147.	0.8	82
114	An Outbreak of Hepatitis A among Cancer Patients Treated with Interleukin-2 and Lymphokine-Activated Killer Cells. Journal of Infectious Diseases, 1990, 161, 647-652.	1.9	36
115	Phase I Study of High-Dose Continuous-Infusion Recombinant Interleukin-2 and Autologous Lymphokine-Activated Killer Cells in Patients With Metastatic or Unresectable Malignant Melanoma and Renal Cell Carcinoma. Journal of the National Cancer Institute, 1990, 82, 1397-1402.	3.0	45
116	A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: A Southwest Oncology Group Study. Gynecologic Oncology, 1990, 39, 332-336.	0.6	63
117	A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: A southwest oncology group trial. Gynecologic Oncology, 1990, 37, 354-358.	0.6	31
118	A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.. Journal of Clinical Oncology, 1989, 7, 477-485.	0.8	236
119	Phase I clinical investigation of amonafide.. Journal of Clinical Oncology, 1989, 7, 1351-1358.	0.8	41
120	Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.. Journal of Clinical Oncology, 1989, 7, 486-498.	0.8	338
121	A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U). European Journal of Cancer & Clinical Oncology, 1989, 25, 1867-1873.	0.9	10
122	Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma. Cancer Treatment Reviews, 1989, 16, 29-38.	3.4	21
123	Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion. European Journal of Cancer & Clinical Oncology, 1989, 25, 797-803.	0.9	14
124	Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells. Annals of Internal Medicine, 1988, 108, 518.	2.0	334
125	Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens.. Journal of Clinical Oncology, 1986, 4, 1827-1834.	0.8	91
126	Second-Line Chemotherapy for Ovarian Cancer. Clinical Obstetrics and Gynecology, 1986, 29, 665-677.	0.6	5



#	ARTICLE	IF	CITATIONS
127	A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1985, 15, 144-148.	1.1	1
128	Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion.. <i>Journal of Clinical Oncology</i> , 1984, 2, 1266-1269.	0.8	28
129	Phase-I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU. <i>Cancer Chemotherapy and Pharmacology</i> , 1984, 13, 136-8.	1.1	8
130	Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump.. <i>Journal of Clinical Oncology</i> , 1983, 1, 337-344.	0.8	130
131	A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 8, 301-4.	1.1	6
132	Testicular Cancer in a Russell-Silver Dwarf. <i>Journal of Urology</i> , 1981, 126, 836-837.	0.2	22
133	Reduction of some halocyclopropanes with sodium naphthalenide. <i>Journal of Organic Chemistry</i> , 1971, 36, 2186-2188.	1.7	9